Adaptive Broadband

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. The company's proprietary Immune Medicine Platform uses high-throughput sequencing and computational biology to read and translate the genetic code of the adaptive immune system at scale. Its core commercial products include clonoSEQ, the first FDA-cleared test for monitoring minimal residual disease (MRD) in blood cancers, and immunoSEQ, a research tool for immunosequencing. Adaptive also maintains significant drug discovery partnerships, most notably a multi-billion dollar collaboration with Genentech to develop personalized TCR-based cellular therapies for cancer.